NeoGenomics Q4 Revenues Up on Strong Test Volume Growth | GenomeWeb

This article has been updated with comments from a conference call following the release of the firm's financial results.

NEW YORK (GenomeWeb) – NeoGenomics reported today a nine percent increase in fourth quarter revenues on increased base test volume growth, helping the firm top Wall Street's consensus estimate.

For the three-month period ended Dec. 31, the cancer genetics testing firm reported revenues of $27.3 million compared to $25 million in the same period the year before. Analysts had, on average, expected revenues of $26.5 million. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.